• In late April 2026, Zimmer Biomet Holdings reported first-quarter 2026 results showing sales of US$2,086.7 million and net income of US$238.1 million, reaffirmed its full-year revenue growth guidance, detailed ongoing share repurchases totaling US$1.48 billion since 2024, and announced the departure of its CFO, with the Controller and Chief Accounting Officer appointed as interim CFO.
• The combination of stronger earnings, benefits from technology platforms and tariffs, continued buybacks, and finance leadership changes sets up 2026 as a transition year where execution on a new specialized sales model becomes a central focus for investors.
• We’ll now examine how Zimmer Biomet’s strong earnings and raised profit guidance, alongside CFO turnover, shape the company’s broader investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Zimmer Biomet Holdings Investment Narrative Recap

To own Zimmer Biomet, you need to believe in steady orthopedic procedure demand, the company’s push into robotics and digital surgery, and its ability to execute a new specialized sales model without disrupting growth. The latest results, with higher earnings and reaffirmed revenue guidance, support that execution story in the near term, while CFO turnover keeps leadership stability and margin delivery as the key risk to watch rather than a clear inflection point.

The most relevant update here is Zimmer Biomet’s raised adjusted EPS and free cash flow guidance following tariff benefits, even as revenue guidance stayed unchanged. For investors, that sharpens the focus on whether technology and robotics driven mix improvements, alongside ongoing buybacks of US$1,479.78 million since 2024, can offset pricing pressures and competitive threats in core hips and knees.

Yet investors should be aware that competition in robotics and core orthopedics could pressure Zimmer Biomet’s market share and...

Zimmer Biomet Holdings' narrative projects $9.2 billion revenue and $1.2 billion earnings by 2029.

Uncover how Zimmer Biomet Holdings' forecasts yield a $102.95 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently value Zimmer Biomet between US$98.52 and US$181.74 per share, underlining how far opinions can spread. You may want to weigh those views against the company’s dependence on successful commercialization of its robotics and digital platforms, which could meaningfully influence future earnings quality and resilience.

Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth just $98.52!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Zimmer Biomet Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.